Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Flamel Technologies — Q2 2016 Earnings Presentation

18 slides from Avadel Pharmaceuticals's earnings presentation, Aug 8, 2016

  1. Slide 1: Second Quarter 2016 Earnings Conference Call

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 1 Second Quarter 2016 Earnings Conference Call August 8, 2016

  2. Slide 2: Forward Looking Statements

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 2 Forward Looking Statements This presentation may include "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forwar

  3. Slide 3: FT228 - Medusa Exenatide Phase 1b PD

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 3 FT228 - Medusa™ Exenatide Phase 1b PD Performance comparable to current marketed products Bydureon ® & Victoza ® Biomarkers / Surrogate Endpoints: • Glycated Hemoglobin (HbA1c) • Fasted Plasma Glucose (FPG) • Weight Loss Favorable Safety

  4. Slide 4: FT227 – Trigger Lock Hydromorphone

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 4 FT227 – Trigger Lock™ Hydromorphone ▪ Completed two pharmacokinetic (PK) studies in 30 healthy volunteers ▪ Independent in vitro study confirming superior resistance to extraction/recovery in various media under several different conditio

  5. Slide 5: LiquiTime Perrigo Partnership

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 5 LiquiTime ® Perrigo Partnership (OTC) ▪ Ibuprofen likely to be lengthy and expensive approval process – evaluating potential replacement product ▪ Guaifenesin slated to begin pivotal trial in 1H 2017 Prescription Products ▪ Feasibility st

  6. Slide 6: FT218 – Micropump Sodium Oxybate

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 6 FT218 – Micropump ® Sodium Oxybate Special Protocol Assessment (SPA) Filed with FDA end of Q1 2016 Dialogue with FDA ▪ No substantive issues ▪ Expect finalization near - term ▪ Overall trial tiamline intact – NDA filing end 2017 / early 2

  7. Slide 7: Bloxiverz, Vazculep & Akovaz

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 7 Bloxiverz ®, Vazculep ® & Akovaz ™ Bloxiverz held between 40% - 45% of neostigmine market during 2Q 2016 Vazculep increased market share in 2Q 2016 • 32% 1mL market volume • 100% 5mL market volume • 100% 10mL market volume Akovaz to launc

  8. Slide 8: FSC Pediatric Products

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 8 FSC Pediatric Products • Sales below expectations, but up ~ $1 million Q/Q • Growth across all products • Flexichamber launched planned for early Q4 • Continue to optimize sales territories, product distribution & 3 rd party payer access

  9. Slide 9: GAAP Financial Results

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 9 GAAP Financial Results Difference - Inc./(Dec.) (in 000s) Q2 2016 Q1 2016 Q2 2015 Q2 2016 vs. Q1 2016 Q2 2016 vs. Q2 2015 Revenue $ 38,858 $ 36,216 $ 48,602 $ 2,642 $ (9,744) Cost of products and services sold 3,907 3,906 2,756 1 1,151 Re

  10. Slide 10: Non-GAAP Financial Results

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 10 Non - GAAP Financial Results Difference - Inc./(Dec.) (in 000s) Q2 2016 Q1 2016 Q2 2015 Q2 2016 vs. Q1 2016 Q2 2016 vs. Q2 2015 Revenue $ 38,858 $ 36,216 $ 48,602 $ 2,642 $ (9,744) Cost of products and services sold 3,145 3,143 2,756 2 3

  11. Slide 11: Product Sales

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 11 Product Sales Difference - Inc./(Dec.) (in 000s) Q2 2016 Q1 2016 Q2 2015 Q2 2016 vs. Q1 2016 Q2 2016 vs. Q2 2015 Bloxiverz $ 25,620 $ 24,747 $ 44,283 $ 873 $ (18,663) Vazculep 10,421 9,406 3,627 1,015 6,794 Other 2,124 1,200 692 924 1,43

  12. Slide 12: Cash Flow Summary

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 12 Cash Flow Summary Six Months Ended June 30, 2016 2015 TOTAL Cash and Marketable Securities Beginning Balance $ 144,802 $ 92,834 Operating Cash Flows (excluding tax and earnout /royalty payments) 36,816 60,176 Tax Payments (13,100) (20,87

  13. Slide 13: Full-Year 2016 Guidance

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 13 Full - Year 2016 Guidance UPDATED PREVIOUS Revenue $125M - $140M $110M - $130M Research & Development Expenses $30M - $40M $35M - $50M

  14. Slide 14: Question & Answer

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 14 Question & Answer

  15. Slide 15: Appendix

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 15 Appendix

  16. Slide 16: GAAP to Non-GAAP Reconciliations: Three Months Ended June 30, 2016

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 16 GAAP to Non - GAAP Reconciliations Three Months Ended June 30, 2016: Adjustments (in thousands - USD$) Exclude Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Purchase accounting adjustments - FSC Contingent relat

  17. Slide 17: GAAP to Non-GAAP Reconciliations: Three Months Ended March 31, 2016

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 17 GAAP to Non - GAAP Reconciliations Three Months Ended March 31, 2016: Adjustments (in thousands - USD$) Exclude Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Purchase accounting adjustments - FSC Contingent rela

  18. Slide 18: GAAP to Non-GAAP Reconciliations: Three Months Ended June 30, 2015

    August 8, 2016 Second Quarter 2016 Earnings Conference Call 18 GAAP to Non - GAAP Reconciliations Three Months Ended June 30, 2015: Adjustments (in thousands - USD$) Exclude Include Income tax expense (benefit) related to adjustments GAAP Intangible asset amortization Foreign exchange (gain)/loss Co

Flamel Technologies — Q2 2016 Earnings Presentation on 6ix